Black Rock Inc. Lumos Pharma, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Lumos Pharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 41,104 shares of LUMO stock, worth $178,391. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,104

Previous 41,104 -0.0%

Holding current value

$178,391

Previous $115,000 17.39%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.64 - $3.22 $6,219 - $7,586	-2,356 Reduced 5.42%	41,104 $115,000
Q3 2023 Nov 13, 2023	SELL	$2.63 - $3.49 $8,731 - $11,586	-3,320 Reduced 7.1%	43,460 $143,000
Q2 2023 Aug 11, 2023	SELL	$3.01 - $4.38 $32,718 - $47,610	-10,870 Reduced 18.86%	46,780 $154,000
Q1 2023 May 12, 2023	BUY	$3.16 - $4.0 $1,459 - $1,848	462 Added 0.81%	57,650 $190,000
Q4 2022 Feb 13, 2023	BUY	$3.05 - $9.52 $216 - $675	71 Added 0.12%	57,188 $206,000
Q3 2022 Nov 14, 2022	SELL	$7.35 - $9.05 $2,829 - $3,484	-385 Reduced 0.67%	57,117 $506,000
Q2 2022 Aug 12, 2022	SELL	$6.68 - $9.39 $13,079 - $18,385	-1,958 Reduced 3.29%	57,502 $444,000
Q1 2022 May 12, 2022	SELL	$6.58 - $10.09 $13,449 - $20,623	-2,044 Reduced 3.32%	59,460 $559,000
Q4 2021 Feb 10, 2022	BUY	$6.84 - $10.04 $4,425 - $6,495	647 Added 1.06%	61,504 $427,000
Q3 2021 Nov 09, 2021	SELL	$7.36 - $11.36 $5,689 - $8,781	-773 Reduced 1.25%	60,857 $579,000
Q2 2021 Aug 11, 2021	BUY	$9.75 - $13.44 $600,892 - $828,307	61,630 New	61,630 $616,000

Others Institutions Holding LUMO

# of Institutions

Shares Held

2.2M

Call Options Held

Put Options Held

View Full List

About LUMOS PHARMA, INC.

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

More about LUMO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account